Article Text

other Versions

PDF
Uveal Melanoma: Management and outcome of patients with extraocular spread
  1. Caren Bellmann,
  2. Livia Lumbroso-Le Rouic,
  3. Christine Levy,
  4. Corine Plancher,
  5. Remi Dendale,
  6. Xavier Sastre-Garau,
  7. Bernard Asselain,
  8. Laurence Desjardins*
  1. 1 Institut Curie, France
  1. Correspondence to: Laurence Desjardins, Insitut Curie, 999, 999, 999, France; laurence.desjardins{at}curie.net

Abstract

Background: Extraocular spread is thought to be a negative prognostic factor on the survival in patients with uveal melanoma. Enucleation was the standard treatment in these patients. Today, depending on the size of the tumour and the type of extraocular extension eye-preserving irradiation treatments, such as proton beams or radioactive plaques may be employed.

Methods: 2256 patients were treated between 2000 and 2007 at the Institut Curie, Paris, France for an uveal melanoma. 67 patients (3.0%) presented an extraocular extension. A retrospective study was performed to evaluate the patients outcome with regard to tumour recurrence and their survival.

Results: Eye-conserving treatment was employed in 38 (52.8%) patients. An enucleation was performed in 29 (47.2%) patients. The median follow-up was 38 (range 7 - 79) months with an overall survival rate at 5-years of 40.4% in enucleated patients and 79.3% in the eye-conserving treatment group (protons n=19, iodine-125 plaque n = 19) (p = 0.01; Kaplan-Meier analysis). No tumour recurrence was observed in any group. Degree of extraocular spread as well as the clinical characteristics tumour location, retinal detachment, ciliary body involvement (p < 0.01; Chi-square test) and tumour thickness (p = 0.04; Chi-square test) influenced the choice of treatment. Age, tumour diameter, involvement of optic nerve, vitreous haemorrhage and the amount of pigment were without any influence.

Conclusion: No tumour recurrence and no lower survival rate were observed in patients receiving an eye-conservative treatment. It may represent thus a therapeutic option in certain patients with extraocular spread.

Statistics from Altmetric.com

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.